Top

Gepubliceerd in:

2008 | OriginalPaper | Hoofdstuk

38 De implanteerbare cardioverter-defibrillator

Auteurs : Prof.Dr. M. J. Schalij, Dr. L. Van Erven

Gepubliceerd in: Cardiologie

Uitgeverij: Bohn Stafleu van Loghum

Samenvatting

In Nederland worden jaarlijks 20.000-30.000 mensen getroffen door een acute circulatie- en ademstilstand. Bij 80% van hen wordt de circulatiestilstand veroorzaakt door een ventriculaire ritmestoornis (ventrikeltachycardie of -fibrilleren: VT/VF). Bij 50% is de aritmie het gevolg van acute ischemie en bij 50% wordt de ritmestoornis niet geluxeerd door ischemie. Momenteel wordt slechts 2-5% van deze patiënten met succes gereanimeerd en opgenomen in een ziekenhuis. De patiënten zonder acute ischemie hebben een kans op een recidief van de ritmestoornis van 20-40% per jaar.

vorige hoofdstuk 37 Katheterablatie van hartritmestoornissen

volgende hoofdstuk 39 Aorta- en mitralisklepafwijkingen

Bardy G, Lee K, Mark D, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Eng J Med. 2005;352:225–37.CrossRef

Borger van der Burg AE, Bax JJ, Boersma E, et al. Impact of viability, ischemia, scar tissue, and revascularization on outcome after aborted sudden death. Circulation. 2003;108:1954–9.CrossRef

Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Eng J Med. 2004;350:2140–50.CrossRef

Buxton A, Lee K, Fisher J, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Eng J Med. 1999;341:1882–90.CrossRef

Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Eng J Med. 2005;352:1539–49.CrossRef

Gatzoulis MA, Till JA, Sommerville J, Redington AN. Mechanoelectrical interaction in tetralogy of Fallot. QRS prolongation relates to right ventricular size and predicts malignant ventricular arrhythmias and sudden death. Circulation. 1995;92:231–7.PubMedCrossRef

Gould PA, Krahn AD, Canadian Heart Rhythm Society Working Group on Device Advisories. Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. JAMA. 2006;295:1907–11.

Kadish A, Dyer A, Daubert J, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Eng J Med. 2004;350:2151–8.CrossRef

Kies P, Boersma E, Bax JJ, et al. Determinants of recurrent ventricular arrhythmia or death in 300 consecutive patients with ischemic heart disease who experienced aborted sudden death: data from the Leiden out-of-hospital cardiac arrest study. J Cardiovasc Electrophysiol. 2005;16:1049–56.PubMedCrossRef

Kies P, Bootsma M, Bax J, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: screening, diagnosis, and treatment. Heart Rhythm. 2006;3:225–34.PubMedCrossRef

Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Eng J Med. 2000;342:365–73.CrossRef

Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Eng J Med. 1980;303:322–4.CrossRef

Moss A, Hall J, Cannom D, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk of ventricular arrhythmias. N Eng J Med. 1996;335:1933–40.CrossRef

Moss A, Zareba W, Hall WJ, Klein H, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Eng J Med. 2002;346:877–83.CrossRef

Rooden CJ van, Molhoek SG, Rosendaal FR. Incidence and risk factors of early venous thrombosis associated with permanent pacemaker leads. J Cardiovasc Electrofysiol. 2004;15:1258–62.CrossRef

Silka MJ, Hardy BG, Menashe VD, Morris CD. A population-based prospective evaluation of risk of sudden death after operation for common congenital heart defects. J Am Coll Cardiol. 1998;32:45–51.

The Antiarrhythmic Versus Implantable Defibrillator (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Eng J Med. 1997;337:1576–83.

Wever EF, Hauer RN, Oomen J, et al. Unfavorable outcome in patients with primary electrical disease who survived an episode of ventricular fibrillation. Circulation. 1993;88:1021–9.PubMedCrossRef

Yap SC, Roos-Hesselink JW, Hoendermis ES, et al. Outcome of implantable cardioverter defibrillators in adults with congenital heart disease: a multi-centre study. Eur Heart J. 2007;28:1854–61.PubMedCrossRef

Zwanziger J, Hall J, Dick AW, et al. The cost effectiveness of implantable cardioverter-defibrillators: Results from the Multicenter Automatic Defribillator Implantation Trial (MADIT II). J Am Coll Cardiol. 2006;47:2310–18.PubMedCrossRef

Titel: 38 De implanteerbare cardioverter-defibrillator
Auteurs: Prof.Dr. M. J. Schalij
Dr. L. Van Erven
Uitgeverij: Bohn Stafleu van Loghum
Boek: Cardiologie
Print ISBN: 978-90-313-4829-9

Elektronisch ISBN: 978-90-313-7029-0

Copyright: 2008
DOI: https://doi.org/10.1007/978-90-313-7029-0_38

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen